Related Experiment Video

Updated: Feb 23, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.3K

Update on the clinical use of kinase inhibitors in melanoma

Ioana Cosgarea1, Cathrin Ritter1, Jürgen C Becker1

  • 1Department of Dermatology, Venereology, and Allergology, University Medical Center Essen, University of Duisburg-Essen, Germany, and German Cancer Consortium (DKTK), Essen, Germany.

Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|September 6, 2017
PubMed

Insights

Targeted therapies, including BRAF and MEK inhibitors, offer significant long-term control for melanoma patients. Research is ongoing to overcome resistance with new drug combinations and immunotherapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Targetable molecules in cellular signaling pathways are key in melanoma treatment.
  • Constitutive activation of signaling pathways by gene mutations drives tumor growth.
  • BRAF-mutated melanomas show significant benefit from kinase inhibitor therapies.

Purpose of the Study:

  • To review current targeted therapies for melanoma.
  • To highlight potential future treatment options under clinical investigation.
  • To discuss strategies for overcoming acquired resistance to kinase inhibitors.

Main Methods:

  • Review of current clinical trials and available literature on melanoma targeted therapies.
  • Analysis of the efficacy of combined BRAF and MEK inhibition.
  • Exploration of novel drug combinations and immune checkpoint inhibitors.

Main Results:

  • Combined BRAF and MEK inhibition provides over ten months progression-free survival and two years overall survival.
  • Targeted therapies improve quality of life for melanoma patients.
  • Secondary resistance to kinase inhibitors is a significant challenge in long-term treatment.

Conclusions:

  • Targeted therapies, particularly combined BRAF and MEK inhibition, are effective for BRAF-mutated melanoma.
  • Future research focuses on overcoming resistance through novel drug combinations and immunotherapy.
  • Clinical trials are actively investigating new treatment strategies for melanoma.

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.3K
A 3D Organotypic Melanoma Spheroid Skin Model08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

16.7K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.8K